DEA Extends Telehealth Prescriptions for Opioid Addiction and ADHD Drugs Through 2025
Federal officials announced on Friday that healthcare providers can continue to prescribe drugs for opioid addiction and ADHD through telehealth for another year. This extension resolves a lengthy debate among policymakers about access to these treatments.
During the pandemic, the Drug Enforcement Agency (DEA) allowed providers to prescribe controlled substances, such as buprenorphine and Adderall, without requiring an in-person meeting. These temporary rules were set to end on January 1 but have now been extended to December 31, 2025. This decision pushes the resolution to a future administration.
The pandemic rules sparked discussions about strict regulations that some say limit access to essential treatments. Telehealth companies benefitted from these relaxed regulations during this time. In 2023, the DEA proposed new rules reinstating some restrictions, which telehealth advocates criticized. These proposed rules included requirements for providers to conduct in-person visits for a portion of their controlled substance prescriptions.
When these draft regulations surfaced, telehealth companies expressed concerns that they would lead to service shutdowns. It became clear that the DEA would need to extend the pandemic rules because it lacked the time to finalize new regulations before the year’s end.
How do telehealth regulations impact access to mental health care?
Interview with Dr. Emily Carter, Addiction Specialist and Telehealth Advocate
News Directory 3: Thank you for joining us, Dr. Carter. The extension of telehealth prescriptions for controlled substances has been a significant development. What are your thoughts on this decision?
Dr. Emily Carter: Thank you for having me. I believe this extension is a crucial step forward in ensuring that patients have continued access to essential treatments for opioid use disorder and ADHD. The temporary regulations implemented during the pandemic proved beneficial for many individuals who rely on these medications, particularly those in rural or underserved areas.
News Directory 3: The extension pushes the resolution of this issue to a future administration. How do you foresee this affecting patient care moving forward?
Dr. Carter: The uncertainty in regulations can create anxiety for both providers and patients. However, allowing this extension until December 2025 gives us additional time to gather data on the effectiveness of telehealth. Hopefully, this will inform a more permanent solution that maintains access while also ensuring patient safety.
News Directory 3: There have been concerns about excessive regulations and their potential impact on treatment access. What balance do you think should be struck between oversight and accessibility?
Dr. Carter: It’s a delicate balance. Oversight is necessary to prevent abuse and ensure that prescriptions are appropriate. However, we must avoid creating barriers that could discourage individuals from seeking care. The increased scrutiny surrounding telehealth after incidents of overprescribing highlights the need for more robust and nuanced regulations that prioritize patient well-being without stifling access.
News Directory 3: There are ongoing discussions about the DEA’s proposed new regulations regarding in-person visits. What are your concerns about these proposed changes?
Dr. Carter: My primary concern is the potential reintroduction of barriers that could limit access for patients who benefit significantly from telehealth. For example, requiring in-person visits could disproportionately affect those with mobility issues, transportation challenges, or those living in remote areas. While some oversight is essential, we should also recognize the successful, safe practices that have developed during the pandemic.
News Directory 3: Following the arrests of several telehealth company leaders for illegal distribution, there seems to be growing scrutiny on the industry. How can telehealth services address these concerns while still providing care?
Dr. Carter: Telehealth companies must prioritize compliance and ethical prescribing practices. This means investing in thorough evaluation processes for both patients and providers. Transparency and accountability should be at the forefront of their operations. By demonstrating a commitment to best practices, they can build trust with regulators and patients alike.
News Directory 3: do you believe that Congress will support the extension of telehealth policies for Medicare enrollees? What would that mean for healthcare access?
Dr. Carter: I am optimistic that Congress will recognize the value of extending telehealth services. For Medicare enrollees, continued access to these services could mean the difference between receiving vital care or going without. The pandemic has shown us how effective telehealth can be in reaching marginalized populations, and I hope lawmakers will see the importance of supporting these advancements in healthcare accessibility.
News Directory 3: Thank you, Dr. Carter, for your insights on this important issue. Your expertise sheds light on the complexities surrounding telehealth and controlled substances.
Dr. Carter: Thank you for having me. It’s essential that we continue the conversation about ensuring access to care while safeguarding against misuse.
The draft rules were viewed by some as an attack on companies that overprescribe stimulants for profit. In June, leaders of an ADHD telehealth company were arrested for allegedly distributing controlled substances illegally. The one-year extension aims to prevent investments in telehealth companies that might engage in problematic prescribing practices.
While many acknowledge the need for oversight to prevent abuse, they worry that excessive restrictions could harm progress made in addiction treatment. Advocates for buprenorphine access highlight the urgent need for continued telehealth services for opioid use disorder.
The temporary extension also addresses one of several telehealth policies set to expire this year. Congress is currently considering extending rules that permit Medicare enrollees to access a variety of services through telehealth for an additional two years.